# A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

> **NCT07752407** · PHASE3 · RECRUITING · sponsor: **Phathom Pharmaceuticals, Inc.** · enrollment: 500 (estimated)

## Conditions studied

- Symptomatic Non-erosive Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Vonoprazan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07752407
- **Lead sponsor:** Phathom Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-25
- **Primary completion:** 2027-10-20
- **Final completion:** 2028-01-19
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07752407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07752407, "A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07752407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*